Abivax (ABVX) Goodwill & Intangibles (2021 - 2026)
Abivax (ABVX) posted quarterly Goodwill & Intangibles of $29.3 million for Q1 2026, up 11.3% year-over-year from $26.3 million in Q1 2025, and up 0.58% quarter-over-quarter from $29.1 million in Q4 2025.
Abivax (ABVX) Goodwill & Intangibles (2021 - 2026) Analysis & Trends
Abivax's Goodwill & Intangibles history runs 6 years deep, the most recent figure standing at $29.3 million for Q1 2026.
- In Q1 2026, Goodwill & Intangibles rose 11.3% year-over-year to $29.3 million; the TTM figure through Mar 2026 stood at $29.3 million (up 11.3% YoY), while the FY2025 annual figure was $29.1 million, up 8.93% from the prior year.
- Goodwill & Intangibles for Q1 2026 stood at $29.3 million, up from $29.1 million in the prior quarter.
- The five-year high for Goodwill & Intangibles was $29.3 million in Q1 2026, with the low at $25.5 million in Q4 2022.
- The 5-year median for Goodwill & Intangibles is $27.0 million (2024), against an average of $27.6 million.
- The sharpest annual moves came in 2022 and 2026: Goodwill & Intangibles slumped 30.46% in 2022, then climbed 11.3% in 2026.
- Abivax's Goodwill & Intangibles stood at $25.5 million in 2022, then advanced by 5.45% to $26.9 million in 2023, then dropped by 0.67% to $26.7 million in 2024, then increased by 8.93% to $29.1 million in 2025, then rose by 0.58% to $29.3 million in 2026.
- Business Quant data shows ABVX's Goodwill & Intangibles at $29.3 million in Q1 2026, $29.1 million in Q4 2025, and $29.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.30 Mn |
| Dec 31, 2025 | 29.13 Mn |
| Sep 30, 2025 | 29.26 Mn |
| Jun 30, 2025 | 28.33 Mn |
| Mar 31, 2025 | 26.32 Mn |
| Dec 31, 2024 | 26.74 Mn |
| Jun 30, 2024 | 26.95 Mn |
| Dec 31, 2023 | 26.92 Mn |
| Dec 31, 2022 | 25.53 Mn |
| Dec 31, 2021 | 36.72 Mn |